Literature DB >> 31586519

Immunomodulatory Drugs Encoded by Oncolytic Viruses: Is the Whole Greater Than the Sum?

Dmitriy Zamarin1.   

Abstract

Year:  2019        PMID： 31586519      PMCID： PMC6839000          DOI： 10.1016/j.ymthe.2019.09.022

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  12 in total

Review 1.  Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.

Authors:  Spencer C Wei; Colm R Duffy; James P Allison
Journal:  Cancer Discov       Date:  2018-08-16       Impact factor: 39.397

2.  Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8+ T Cells in HCC.

Authors:  Yonghui Zhang; Hailin Zhang; Mei Wei; Tao Mou; Tao Shi; Yanyu Ma; Xinyu Cai; Yunzheng Li; Jie Dong; Jiwu Wei
Journal:  Mol Ther       Date:  2019-08-05       Impact factor: 11.454

Review 3.  Optimizing oncolytic virotherapy in cancer treatment.

Authors:  Kevin Harrington; Daniel J Freeman; Beth Kelly; James Harper; Jean-Charles Soria
Journal:  Nat Rev Drug Discov       Date:  2019-07-10       Impact factor: 84.694

Review 4.  In-situ tumor vaccination: Bringing the fight to the tumor.

Authors:  Robert H Pierce; Jean S Campbell; Sara I Pai; Joshua D Brody; Holbrook E K Kohrt
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.

Authors:  Neil H Segal; Theodore F Logan; F Stephen Hodi; David McDermott; Ignacio Melero; Omid Hamid; Henrik Schmidt; Caroline Robert; Vanna Chiarion-Sileni; Paolo A Ascierto; Michele Maio; Walter J Urba; Tara C Gangadhar; Satyendra Suryawanshi; Jaclyn Neely; Maria Jure-Kunkel; Suba Krishnan; Holbrook Kohrt; Mario Sznol; Ronald Levy
Journal:  Clin Cancer Res       Date:  2016-10-18       Impact factor: 12.531

Review 6.  Targeting T Cell Co-receptors for Cancer Therapy.

Authors:  Margaret K Callahan; Michael A Postow; Jedd D Wolchok
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

7.  Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses.

Authors:  Maria Cristina Ballesteros-Briones; Eva Martisova; Erkuden Casales; Noelia Silva-Pilipich; Maria Buñuales; Javier Galindo; Uxua Mancheño; Marta Gorraiz; Juan J Lasarte; Grazyna Kochan; David Escors; Alfonso R Sanchez-Paulete; Ignacio Melero; Jesus Prieto; Ruben Hernandez-Alcoceba; Sandra Hervas-Stubbs; Cristian Smerdou
Journal:  Mol Ther       Date:  2019-09-16       Impact factor: 11.454

8.  Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.

Authors:  Aurélien Marabelle; Holbrook Kohrt; Idit Sagiv-Barfi; Bahareh Ajami; Robert C Axtell; Gang Zhou; Ranjani Rajapaksa; Michael R Green; James Torchia; Joshua Brody; Richard Luong; Michael D Rosenblum; Lawrence Steinman; Hyam I Levitsky; Victor Tse; Ronald Levy
Journal:  J Clin Invest       Date:  2013-06       Impact factor: 14.808

9.  Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects.

Authors:  Marieke F Fransen; Tetje C van der Sluis; Ferry Ossendorp; Ramon Arens; Cornelis J M Melief
Journal:  Clin Cancer Res       Date:  2013-06-20       Impact factor: 12.531

Review 10.  Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer.

Authors:  Dmitriy Zamarin; Jedd D Wolchok
Journal:  Mol Ther Oncolytics       Date:  2014-12-10       Impact factor: 7.200
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.